Stay updated on Asciminib Combo with Imatinib in CML-CP Clinical Trial
Sign up to get notified when there's something new on the Asciminib Combo with Imatinib in CML-CP Clinical Trial page.

Latest updates to the Asciminib Combo with Imatinib in CML-CP Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe Locations section is updated to include Georgia, Maryland, Quebec, MI, RM, Gyeonggi-do, Seocho Gu, Andalusia, and Catalonia, and the previous location blocks are removed or reorganized accordingly.SummaryDifference0.7%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedMinor editorial notes were added to clarify that publications are automatically filled from PubMed and that the revision was updated to v3.3.2; the older PubMed note and revision v3.2.0 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedAdded 'Last Update Posted (Estimated)' timestamp to the Study Details page and removed the government funding status notice that previously appeared.SummaryDifference0.3%

- Check55 days agoChange DetectedExplicitly added secondary outcome definitions for MR^4.5, including best observed MR^4.5 rate up to 48 weeks, MR^4.5 rate at 96 weeks, and best observed MR^4.5 rate up to 96 weeks, and added a 'Last Update Posted' timestamp.SummaryDifference0.3%

- Check63 days agoChange Detected- The page now includes results-related information (Results First Posted date) and an updated Study Completion date, reflecting the current timeline for the trial and availability of results.SummaryDifference0.3%

- Check91 days agoChange DetectedAdded a government-operating-status notice and new version v3.2.0; removed old version v3.1.0.SummaryDifference3%

Stay in the know with updates to Asciminib Combo with Imatinib in CML-CP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Asciminib Combo with Imatinib in CML-CP Clinical Trial page.